Dana-Farber Cancer Institute at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Dana-Farber Cancer Institute brings 7 presentations to ASH 2026 in New Orleans. Its program covers targeted and immune therapies across lymphoma, leukemia and myeloma, from BTK inhibitors in CLL to protein degraders in myeloma. It also covers the MLL (KMT2A) complex as a route to new leukemia drugs and CAR T manufacturing that could widen access in lower-income countries.
| Organization | ASH 2026 Attendance |
|---|---|
Dana-Farber Cancer Institute Boston, MA | |
Harvard-affiliated cancer treatment and research center in Boston, Massachusetts. | Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Symposium Fri Dec 11 11:00am–2:00pm Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia. Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium Fri Dec 11 7:00am–10:00am MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia. Symposium Fri Dec 11 7:00pm–10:00pm Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs. Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. Session Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS Single-cell and spatial maps of bone marrow in acute myeloid leukemia and myelodysplastic neoplasms, showing how immune cell niches help tumors evade immunity. Session Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward Old and new tools, from biochemistry and mouse models to spatial gene mapping and AI, revealing weak points and treatment biomarkers in multiple myeloma. Talk Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function Structural biology uncovered a second route for destroying the transcription factors multiple myeloma depends on, making that pathway a possible drug target. Talk From Frontier to Field: Manufacturing Innovations That Could Lower Barriers to CAR-T Access in LMICs Manufacturing advances from wealthy countries that could make CAR-T therapy cheaper and easier to deliver in low- and middle-income countries. Talk Targeting Acute and Chronic GVHD with Effective New Therapies Recently approved treatments for steroid-resistant acute and chronic graft-versus-host disease, including ruxolitinib, belumosudil, axatilimab and stromal cells. Talk Dealing with Workforce Challenges in Classical Hematology What drives the shortage of specialists in non-cancer blood disorders, and early results from efforts to close the gap. |
Instantly find 20 buyers from Dana-Farber Cancer Institute
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction